US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
JPS63501765A
(ja)
|
1985-11-01 |
1988-07-21 |
インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド |
抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
JP3771253B2
(ja)
|
1988-09-02 |
2006-04-26 |
ダイアックス コープ. |
新規な結合タンパク質の生成と選択
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
CA2089661C
(en)
|
1990-08-29 |
2007-04-03 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
AU664976B2
(en)
|
1990-08-29 |
1995-12-14 |
Gene Pharming Europe Bv |
Homologous recombination in mammalian cells
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
EP1820858B1
(en)
|
1991-03-01 |
2009-08-12 |
Dyax Corporation |
Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
|
CA2108147C
(en)
|
1991-04-10 |
2009-01-06 |
Angray Kang |
Heterodimeric receptor libraries using phagemids
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
ATE452207T1
(de)
|
1992-08-21 |
2010-01-15 |
Univ Bruxelles |
Immunoglobuline ohne leichte ketten
|
US5480974A
(en)
|
1993-06-18 |
1996-01-02 |
The Scripps Research Institute |
Antibodies to human C5a receptor
|
BR0213761A
(pt)
|
2001-10-25 |
2005-04-12 |
Genentech Inc |
Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
|
US8071096B2
(en)
|
2002-01-25 |
2011-12-06 |
G2 Therapies Ltd |
Anti-C5aR antibodies and uses thereof
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
BRPI0314814C1
(pt)
|
2002-09-27 |
2021-07-27 |
Xencor Inc |
anticorpo compreendendo uma variante de fc
|
AU2003290605A1
(en)
|
2002-11-05 |
2004-06-03 |
The Regents Of The University Of Michigan |
Compositions and methods for the diagnosis and treatment of sepsis
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
DE602004017439D1
(de)
|
2003-03-17 |
2008-12-11 |
Bayer Healthcare Ag |
Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
|
JP2007503206A
(ja)
|
2003-08-22 |
2007-02-22 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
WO2005050199A1
(en)
|
2003-10-31 |
2005-06-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g protein- coupled receptor 77 (gpr77)
|
US8071839B2
(en)
|
2003-12-24 |
2011-12-06 |
G2 Inflammation Pty Ltd |
Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
|
EP2154157A3
(en)
|
2004-01-12 |
2010-04-28 |
Applied Molecular Evolution Inc. |
FC region variants
|
KR100863776B1
(ko)
|
2004-07-15 |
2008-10-16 |
젠코어 인코포레이티드 |
최적화된 Fc 변이체
|
EP1810035A4
(en)
|
2004-11-10 |
2010-03-17 |
Macrogenics Inc |
EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS
|
RU2009110154A
(ru)
|
2006-08-22 |
2010-09-27 |
Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) |
АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
|
WO2008022391A1
(en)
|
2006-08-22 |
2008-02-28 |
G2 Inflammation Pty Ltd |
Method for producing antibodies
|
US8815237B2
(en)
|
2007-12-05 |
2014-08-26 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
US8268972B2
(en)
|
2008-02-20 |
2012-09-18 |
G2 Inflammation Pty Ltd |
Humanized anti-C5aR antibodies
|
WO2009108931A2
(en)
|
2008-02-28 |
2009-09-03 |
Case Western Reserve University |
Method of treating cancer
|
US20180256646A1
(en)
|
2008-03-06 |
2018-09-13 |
Case Western Reserve University |
Compositions and methods for modulating toll like receptor signal
|
RU2583298C2
(ru)
|
2009-10-07 |
2016-05-10 |
Макродженикс, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
LT2506871T
(lt)
|
2009-11-30 |
2016-12-12 |
Janssen Biotech, Inc. |
Antikūno fc mutantai su pašalinta efektoriaus funkcija
|
US10053513B2
(en)
|
2009-11-30 |
2018-08-21 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
WO2011100477A2
(en)
*
|
2010-02-10 |
2011-08-18 |
Taiga Biotechnologies, Inc. |
Antibodies and processes for preparing the same
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
US11130801B2
(en)
|
2011-01-13 |
2021-09-28 |
Case Western Reserve University |
Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
|
US8952132B2
(en)
|
2011-02-07 |
2015-02-10 |
Research Development Foundation |
Engineered immunoglobulin FC polypeptides
|
SG10201609665PA
(en)
|
2011-02-25 |
2017-01-27 |
Chugai Pharmaceutical Co Ltd |
FcɣRIIb-SPECIFIC Fc ANTIBODY
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
EP3825325A3
(en)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
DK2718322T3
(en)
|
2011-06-06 |
2018-12-03 |
Novo Nordisk As |
THERAPEUTIC ANTIBODIES
|
CN109517059B
(zh)
|
2011-06-30 |
2023-03-28 |
中外制药株式会社 |
异源二聚化多肽
|
WO2013004841A1
(en)
|
2011-07-06 |
2013-01-10 |
Genmab A/S |
Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
EP2844289B1
(en)
|
2012-04-30 |
2019-07-17 |
MedImmune, LLC |
Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
|
EP2862875B1
(en)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
CN104640562A
(zh)
|
2012-07-13 |
2015-05-20 |
酵活有限公司 |
包含抗-cd3构建体的双特异性不对称异二聚体
|
TW202340236A
(zh)
|
2012-08-24 |
2023-10-16 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
CA2904805A1
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
US20160060351A1
(en)
|
2013-05-08 |
2016-03-03 |
Novo Nordisk A/S |
Use of C5AR Antagonists
|
AU2014273817B2
(en)
|
2013-05-31 |
2019-03-14 |
Zymeworks Bc Inc. |
Heteromultimers with reduced or silenced effector function
|
BR122020019190B1
(pt)
|
2013-08-07 |
2023-11-21 |
Alexion Pharmaceuticals, Inc. |
Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus
|
EA038349B1
(ru)
|
2014-11-21 |
2021-08-12 |
Бристол-Маерс Сквибб Компани |
Антитела, содержащие модифицированные константные участки тяжелой цепи
|
TWI779010B
(zh)
|
2014-12-19 |
2022-10-01 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
EP3349773A4
(en)
|
2015-09-14 |
2019-05-01 |
Cincinnati Children's Hospital Medical Center |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF LEFT-HALF DISEASE VIA C5A RECEPTOR MODULATION
|
CA3032820A1
(en)
|
2016-08-02 |
2018-03-22 |
Visterra, Inc. |
Engineered polypeptides and uses thereof
|
AU2017338291A1
(en)
|
2016-10-06 |
2019-03-14 |
Glaxosmithkline Intellectual Property Development Limited |
Antibodies with reduced binding to process impurities
|
FR3058159B1
(fr)
|
2016-10-28 |
2022-02-25 |
Lab Francais Du Fractionnement |
Variants de polypeptide fc presentant une demi-vie augmentee
|
CA3049689A1
(en)
|
2017-02-06 |
2018-08-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
WO2018183520A1
(en)
|
2017-03-28 |
2018-10-04 |
Lyvgen Biopharma Holdings Limited |
Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
|
ES2893769T3
(es)
|
2017-04-03 |
2022-02-10 |
Inflarx Gmbh |
Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a
|
JP7264381B2
(ja)
|
2017-04-07 |
2023-04-25 |
国民大学校産学協力団 |
血中半減期の向上のための抗体Fc変異体
|
US20200148779A1
(en)
|
2017-05-25 |
2020-05-14 |
Bristol-Myers Squibb Company |
MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
|
KR20200013241A
(ko)
|
2017-05-25 |
2020-02-06 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
JP2020522543A
(ja)
|
2017-06-07 |
2020-07-30 |
ゲンマブ ビー.ブイ. |
変異IgG六量体に基づく治療用抗体
|
SG11201912882QA
(en)
*
|
2017-06-23 |
2020-01-30 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of c5a activity
|
JP2021501159A
(ja)
|
2017-10-31 |
2021-01-14 |
ケモセントリックス,インコーポレイティド |
C5aR阻害剤による尿中sCD163の減少
|
AU2018388791A1
(en)
|
2017-12-19 |
2020-07-16 |
The Rockefeller University |
Human IgG Fc domain variants with improved effector function
|
US20210070860A1
(en)
|
2018-03-21 |
2021-03-11 |
Dana-Farber Cancer Institute, Inc. |
Fc variant compositions and methods of use thereof
|
US20200376135A1
(en)
|
2018-10-23 |
2020-12-03 |
Magenta Therapeutics, Inc. |
Fc silenced antibody drug conjugates (adcs) and uses thereof
|
CN113348177A
(zh)
|
2018-11-28 |
2021-09-03 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
MA55285A
(fr)
*
|
2019-03-14 |
2022-01-19 |
Morphosys Ag |
Anticorps ciblant c5ar
|
WO2021041715A2
(en)
|
2019-08-30 |
2021-03-04 |
University Of Kansas |
Compositions including igg fc mutations and uses thereof
|
TW202140553A
(zh)
|
2020-01-13 |
2021-11-01 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
WO2021180063A1
(en)
|
2020-03-09 |
2021-09-16 |
I-Mab Biopharma Co., Ltd. |
Methods for detecting and quantifying biological modifications in antibodies
|
AU2020438234A1
(en)
|
2020-03-27 |
2022-09-29 |
Inflarx Gmbh |
Inhibitors of C5a for the treatment of corona virus infection
|
US11912781B2
(en)
*
|
2021-01-13 |
2024-02-27 |
Visterra, Inc. |
Humanized complement 5A receptor 1 antibodies and methods of use thereof
|